Laurent Fischer
CIK: 0001379344
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (47 total)
- Oct 22, 2026LYCA
Lycia Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20K shares- - Sep 11, 2026ATAI
AtaiBeckley Inc.
Disposition(D)DirectStock Option
122K shares- - Sep 11, 2026ATAI
AtaiBeckley Inc.
Disposition(D)DirectStock Option
103K shares- - Sep 11, 2026ATAI
AtaiBeckley Inc.
Disposition(D)DirectStock Option
206K shares- - Aug 11, 2026LYCA
Lycia Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
13.3K shares- - Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectDeferred Stock Units
2K shares- - Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 4, 2026ATAI
AtaiBeckley Inc.
Award(A)DirectStock Option
122K shares- - May 29, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct4K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Exercise(M)Direct150K shares at avg. $4.20$630K - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
45.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
63K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Tender Offer(U)Direct522.7K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
93K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
31.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
58.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
67.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
110.4K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
200K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
68K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Tender Offer(U)Direct25K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Award(A)Direct500K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
120K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Tender Offer(U)Direct351.5K shares- - Dec 8, 2025ADVM
Adverum Biotechnologies, Inc.
Purchase(P)Direct117.6K shares at avg. $4.31$507K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 22, 2026 |  LYCA Lycia Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Sep 11, 2026 |  ATAI AtaiBeckley Inc. | Disposition(D) Stock Option | 121,968 | - | - | Direct |
| Sep 11, 2026 | ATAI AtaiBeckley Inc. | Disposition(D) Stock Option | 103,000 | - | - | Direct |
| Sep 11, 2026 | ATAI AtaiBeckley Inc. | Disposition(D) Stock Option | 206,000 | - | - | Direct |
| Aug 11, 2026 | LYCA Lycia Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 13,307 | - | - | Direct |
| Jun 15, 2026 |  MIRM Mirum Pharmaceuticals, Inc. | Award(A) Deferred Stock Units | 1,980 | - | - | Direct |
| Jun 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,772 | - | - | Direct |
| Jun 4, 2026 | ATAI AtaiBeckley Inc. | Award(A) Stock Option | 121,968 | - | - | Direct |
| May 29, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 3,977 | - | $0 | Direct |
| Dec 9, 2025 |  ADVM Adverum Biotechnologies, Inc. | Exercise(M) | 150,000 | $4.20 | $630,000 | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 45,499 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 63,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Tender Offer(U) | 522,666 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 93,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 31,500 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 58,497 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 67,502 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 110,420 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 200,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 68,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Tender Offer(U) | 25,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Award(A) | 500,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 120,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Tender Offer(U) | 351,513 | - | - | Direct |
| Dec 8, 2025 | ADVM Adverum Biotechnologies, Inc. | Purchase(P) | 117,614 | $4.31 | $506,916 | Direct |
1-25 of 47 transactions
About Fischer Laurent
Fischer Laurent (SEC CIK 0001379344) files insider reports with the SEC as Director of Lycia Therapeutics, Inc. (LYCA), Director of AtaiBeckley Inc. (ATAI) and Director of Mirum Pharmaceuticals, Inc. (MIRM). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 13 ownership filings by Fischer Laurent (1 Form 3, 12 Form 4), filed between Feb 27, 2025 and Oct 26, 2026. Those filings report 47 transactions, from Feb 25, 2025 to Oct 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fischer Laurent's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Fischer Laurent
- Oct 22, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
- Sep 11, 2026: Disposition to issuer transactions of ATAI derivative securities (3 lines, Form 4, code D).
- Aug 11, 2026: Grant or award of LYCA derivative securities (Form 4, code A).
- Jun 15, 2026: Grants or awards of MIRM derivative securities (2 lines, Form 4, code A).
- Jun 4, 2026: Grant or award of ATAI derivative securities (Form 4, code A).
Other insiders filing for Lycia Therapeutics, Inc. (LYCA)
- Venrock Healthcare Capital Partners III, L.P., 10% Owner
- Versant Ventures VII GP, L.P., 10% Owner
- Henderson Jane, Director
- RIEFLIN WILLIAM JL, Director
- Touami Sofia, Chief Business Officer
- Staben Steven, Chief Scientific Officer